Compare ODFL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODFL | TEVA |
|---|---|---|
| Founded | 1934 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 40.5B |
| IPO Year | 1996 | 1996 |
| Metric | ODFL | TEVA |
|---|---|---|
| Price | $212.20 | $36.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $190.15 | $38.63 |
| AVG Volume (30 Days) | 1.7M | ★ 5.5M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | ★ 2.82 | N/A |
| Revenue | ★ $5,496,389,000.00 | N/A |
| Revenue This Year | $4.41 | N/A |
| Revenue Next Year | $9.04 | $2.97 |
| P/E Ratio | $74.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.01 | $17.33 |
| 52 Week High | $252.03 | $37.39 |
| Indicator | ODFL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 66.66 |
| Support Level | $208.80 | $30.42 |
| Resistance Level | $221.63 | $37.17 |
| Average True Range (ATR) | 7.25 | 1.04 |
| MACD | -0.58 | 0.30 |
| Stochastic Oscillator | 31.55 | 82.76 |
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with roughly 260 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are well above those of its peers. Strategic initiatives focus on increasing network density through market-share gains and on maintaining industry-leading service (including ultralow cargo claims) through steadfast infrastructure investment.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.